Title:
A FUSION PROTEIN AS A SUBUNIT VACCINE IMMUNOGEN AGAINST SARS-COV-2 AND THE PREPARATION THEREOF
Document Type and Number:
WIPO Patent Application WO/2023/220842
Kind Code:
A1
Abstract:
Provided is a fusion protein as a subunit vaccine immunogen against SARS-CoV-2 comprising of receptor binding domain (RBD) fragment of SARS-CoV-2 spike protein and Tetanus toxoid fragment P2, they are fused by a linker sequence. Also provided is a method of obtaining the fusion protein.
Inventors:
LIU XIAOLIN (CN)
LIV HONGLIANG (CN)
ZHANG WENHONG (CN)
BI SHENGLI (CN)
LIV HONGLIANG (CN)
ZHANG WENHONG (CN)
BI SHENGLI (CN)
Application Number:
PCT/CN2022/000090
Publication Date:
November 23, 2023
Filing Date:
May 19, 2022
Export Citation:
Assignee:
SHENZHEN GENIUS BIOTECH SERVICE CO LTD (CN)
International Classes:
C07K14/165; A61K39/215; C07K19/00; C12N15/50; C12N15/63
Domestic Patent References:
| WO2022042542A1 | 2022-03-03 | |||
| WO2015176586A1 | 2015-11-26 | |||
| WO2021213924A1 | 2021-10-28 |
Foreign References:
| CN111533809A | 2020-08-14 | |||
| CN112225814A | 2021-01-15 | |||
| CN114163504A | 2022-03-11 |
Other References:
SU QIU-DONG, ZOU YE-NING, YI YAO, SHEN LI-PING, YE XIANG-ZHONG, ZHANG YANG, WANG HUI, KE HONG, SONG JING-DONG, HU KE-PING, CHENG B: "Recombinant SARS-CoV-2 RBD with a built in T helper epitope induces strong neutralization antibody response", VACCINE, ELSEVIER, AMSTERDAM, NL, vol. 39, no. 8, 22 February 2021 (2021-02-22), AMSTERDAM, NL , pages 1241 - 1247, XP055902509, ISSN: 0264-410X, DOI: 10.1016/j.vaccine.2021.01.044
Attorney, Agent or Firm:
KELONG INTERNATIONAL INTELLECTUAL PROPERTY AGENCY LTD. (CN)
Download PDF: